Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Jessica R. Allegretti et al.|Gastroenterology|2023Cited by 97
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Jessica R. Allegretti et al.|The Lancet|2024Cited by 95
OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept studyB E Sands, Julián Panés, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2022Cited by 33
OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12Axel Dignaß, Jessica R. Allegretti, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2022Cited by 17
759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDYDavid T. Rubin, Axel Dignaß, Jessica R. Allegretti et al.|Gastroenterology|2024Cited by 14